Stockscreener 앱 받기
17.96
2.10%
0.37
전일 마감가:
$17.59
열려 있는:
$17.59
하루 거래량:
160.47K
Relative Volume:
0.48
시가총액:
$577.59M
수익:
$4.12M
순이익/손실:
$-56.68M
주가수익비율:
-3.2402
EPS:
-5.5429
순현금흐름:
$-51.44M
1주 성능:
+1.58%
1개월 성능:
-17.24%
6개월 성능:
-27.23%
1년 성능:
-17.39%
1일 변동 폭
$17.50
$18.19
1주일 범위
$16.91
$18.45
52주 변동 폭
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
929-999-4055
주소
7 TIMES SQUARE, NEW YORK
DNTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
17.96 | 568.59M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | TD Cowen | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-26 | 개시 | Robert W. Baird | Outperform |
| 2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 개시 | H.C. Wainwright | Buy |
| 2024-02-15 | 개시 | Stifel | Buy |
| 2023-12-26 | 개시 | Jefferies | Buy |
| 2023-11-22 | 개시 | Wedbush | Outperform |
| 2023-10-30 | 개시 | Guggenheim | Buy |
| 2023-09-28 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-20 | 재개 | Goldman | Neutral |
| 2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 재확인 | B. Riley Securities | Buy |
| 2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-18 | 개시 | B. Riley Securities | Buy |
| 2021-01-07 | 개시 | Mizuho | Buy |
| 2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Millennium Management LLC Has $1.97 Million Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLC - Defense World
BNP Paribas Financial Markets Makes New Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2%Time to Sell? - MarketBeat
Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $53.00 - MarketBeat
Deutsche Bank AG Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - The Manila Times
Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan
Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Point72 Asset Management L.P. Reduces Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Vestal Point Capital LP - MarketBeat
Dianthus Therapeutics appoints new board member By Investing.com - Investing.com India
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - citybiz
Dianthus Therapeutics appoints new board member - Investing.com Australia
Dianthus Therapeutics Announces Board Changes and Elections - TipRanks
Former Novartis-Acquired CEO Joins Dianthus Board Ahead of Critical Phase 2 Data - Stock Titan
Janus Henderson Group PLC Buys 136,314 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment - TipRanks
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Raised by Octagon Capital Advisors LP - MarketBeat
Robert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Wedbush Research Analysts Raise Earnings Estimates for DNTH - Defense World
HC Wainwright Issues Positive Forecast for DNTH Earnings - Defense World
Tower Research Capital LLC TRC Sells 944 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Robert W. Baird Issues Pessimistic Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1% Following Analyst Downgrade - Defense World
DNTH: HC Wainwright & Co. Reiterates Buy Rating with $40 Target - GuruFocus
DNTH Stock Target Price Lowered by Analyst Baird | DNTH Stock Ne - GuruFocus
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views - Benzinga
Wedbush Adjusts Price Target on Dianthus Therapeutics to $34 From $36, Maintains Outperform Rating - marketscreener.com
Dianthus (DNTH) Target Price Adjusted Amid Q1 Pipeline Update | - GuruFocus
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results - The Manila Times
Dianthus Therapeutics Reports Increased R&D Expenses - TipRanks
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Lifted by Braidwell LP - MarketBeat
Avidity Partners Management LP Lowers Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.54%
자본화:
|
볼륨(24시간):